Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Markets are dipping lower this month, but positive news from the FDA has this biotech stock ripping higher.

Shares of Regeneron Pharmaceuticals ( REGN 0.56%), a biotech giant, have been southbound over the past two years as the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer was recently asked about. A caller asked if the stock, up 54% from its “summer lows”, can continue its momentum. Here’s ...

Shares of Regeneron Pharmaceuticals Inc. slipped 3.86% to $750.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.53% to 6,812.

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; investors are trying to figure out if the current price really reflects its long ...

Investing.com --- HSBC initiated coverage of Regeneron with a Buy rating, saying the drugmaker is positioned to grow faster than the market expects as demand for Eylea HD improves and key oncology ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

While the company is making efforts to diversify its revenue base and develop its oncology franchise, Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.

This was the stock's fifth consecutive day of losses.